Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

- March 13th, 2018

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential … Continued

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential path forward for the approval of Twirla,” stated Al Altomari, Chairman and Chief Executive Officer of Agile. “We believe that Twirla, if approved, will provide women with a new contraceptive option in the form of a patch that is designed to deliver a low dose of estrogen and offer greater convenience for women.”

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Leave a Reply

Your email address will not be published. Required fields are marked *